Time-dose factors in radiotherapy: a review of the human data
- PMID: 2281152
- DOI: 10.1016/0167-8140(90)90149-q
Time-dose factors in radiotherapy: a review of the human data
Abstract
The values for alpha/beta (fractionation sensitivity, or recovery capacity) for early and late reactions in human normal tissues are consistent with results from experimental animals. For breast treatments direct analysis indicates that for early reactions alpha/beta is in the range 7 to 11 Gy, while for late effects it is in the range 2 to 4 Gy. Data on recovery kinetics in human tissues is limited but these indicate that recovery may be slower in humans than in rodents. For early skin reactions the halftime of recovery is about 1 h, while for late telangiectasia it is more than 3 h. alpha/beta values for human tumors are more variable than in rodents: some are high (head and neck, lung, skin, cervix) and similar to those for early reacting normal tissues. Others are low, including melanomas, where alpha/beta was estimated at 0.6 (-1.1, 2.5) Gy, and liposarcomas, where direct analysis of cases surveyed from the literature suggested that alpha/beta = 0.4 (-1.4, 5.4) Gy. Repopulation kinetics is faster in the mucosa of the soft palate and faucial pillars (1.8 Gy/day) than in head and neck tumors (up to 1 Gy/day).
Similar articles
-
Fractionation parameters for human tissues and tumors.Int J Radiat Biol. 1989 Nov;56(5):701-10. doi: 10.1080/09553008914551931. Int J Radiat Biol. 1989. PMID: 2573666 Review.
-
Repair capacity and kinetics for human mucosa and epithelial tumors in the head and neck: clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy.Radiother Oncol. 1996 Feb;38(2):89-101. doi: 10.1016/0167-8140(95)01689-9. Radiother Oncol. 1996. PMID: 8966232 Review.
-
Repair capacity and kinetics of human skin during fractionated radiotherapy: erythema, desquamation, and telangiectasia after 3 and 5 year's follow-up.Radiother Oncol. 1989 Jun;15(2):169-88. doi: 10.1016/0167-8140(89)90131-x. Radiother Oncol. 1989. PMID: 2762590
-
How worthwhile are short schedules in radiotherapy? A series of exploratory calculations.Radiother Oncol. 1990 Jun;18(2):165-81. doi: 10.1016/0167-8140(90)90142-j. Radiother Oncol. 1990. PMID: 2367691
-
The predictive value of skin telangiectasia for late radiation effects in different normal tissues.Int J Radiat Oncol Biol Phys. 1986 Apr;12(4):603-9. doi: 10.1016/0360-3016(86)90069-6. Int J Radiat Oncol Biol Phys. 1986. PMID: 3084405
Cited by
-
Evaluation of acute/late toxicity and local recurrence in T1-T2 glottic carcinoma treated with accelerated hypofractionated 3D-conformal external beam radiotherapy (3D-CRT).Radiol Oncol. 2013 May 21;47(2):185-91. doi: 10.2478/raon-2013-0020. Print 2013 Jun. Radiol Oncol. 2013. PMID: 23801916 Free PMC article.
-
A new view of radiation-induced cancer: integrating short- and long-term processes. Part II: second cancer risk estimation.Radiat Environ Biophys. 2009 Aug;48(3):275-86. doi: 10.1007/s00411-009-0231-2. Epub 2009 Jun 5. Radiat Environ Biophys. 2009. PMID: 19499238 Free PMC article.
-
Clinical Outcomes of Hydrogel Spacer Injection Space OAR in Men Submitted to Hypofractionated Radiotherapy for Prostate Cancer.In Vivo. 2021 Nov-Dec;35(6):3385-3389. doi: 10.21873/invivo.12637. In Vivo. 2021. PMID: 34697173 Free PMC article.
-
Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordoma.Br J Radiol. 2014 Jan;87(1033):20130512. doi: 10.1259/bjr.20130512. Epub 2013 Nov 28. Br J Radiol. 2014. PMID: 24288399 Free PMC article.
-
Who benefits from hypofractionated radiation therapy for clinically localized prostate cancer: evidence from meta-analysis.Tumour Biol. 2014 Oct;35(10):9911-8. doi: 10.1007/s13277-014-2297-y. Epub 2014 Jul 6. Tumour Biol. 2014. PMID: 24997620
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
